https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=ADC_THERAPEUTICS_SAADC THERAPEUTICS SA - Revizia istoricului2026-04-29T21:05:55ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=ADC_THERAPEUTICS_SA&diff=404721&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei ADC THERAPEUTICS SA listata cu simbolul US.ADCT ==Descriere companie== ADC Therapeutics SA (https://adctherapeutics.com/) is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to...2024-09-18T13:35:12Z<p>Pagină nouă: Pagina dedicata companiei ADC THERAPEUTICS SA listata cu simbolul US.ADCT ==Descriere companie== ADC Therapeutics SA (https://adctherapeutics.com/) is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei ADC THERAPEUTICS SA listata cu simbolul US.ADCT<br />
<br />
==Descriere companie==<br />
ADC Therapeutics SA (https://adctherapeutics.com/) is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.ADCT" /><br />
<br />
==Ultimele stiri despre ADC THERAPEUTICS SA (US.ADCT)==<br />
<dynamicpagelist><br />
category=US.ADCT<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.ADCT]][[Categorie:Stiri despre companii]]</div>Admin